GH Research (NASDAQ:GHRS) Research Coverage Started at Guggenheim

Guggenheim started coverage on shares of GH Research (NASDAQ:GHRS) in a research report report published on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $32.00 target price on the stock.

GHRS has been the subject of several other research reports. Cantor Fitzgerald initiated coverage on shares of GH Research in a report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of GH Research in a report on Monday, January 27th. Canaccord Genuity Group decreased their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. Royal Bank of Canada assumed coverage on shares of GH Research in a research note on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Stifel Nicolaus upped their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $30.86.

GH Research Stock Performance

GHRS opened at $11.00 on Thursday. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50. The firm has a market capitalization of $572.31 million, a PE ratio of -13.92 and a beta of 0.94. The company has a fifty day moving average price of $11.13 and a two-hundred day moving average price of $9.18.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. Equities analysts forecast that GH Research will post -0.8 EPS for the current year.

Institutional Investors Weigh In On GH Research

Several institutional investors and hedge funds have recently added to or reduced their stakes in GHRS. Lynx1 Capital Management LP lifted its position in GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after buying an additional 663,100 shares in the last quarter. Diadema Partners LP bought a new stake in GH Research during the 4th quarter worth about $711,000. RA Capital Management L.P. lifted its position in GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock worth $44,734,000 after buying an additional 85,000 shares in the last quarter. Woodline Partners LP lifted its position in GH Research by 112.0% during the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after buying an additional 41,711 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in GH Research during the 4th quarter worth about $145,000. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).